
OPRX
USDOptimizeRx Corporation Common Stock
Reaalajas hind
Hinnagraafik
Põhinäitajad
Turunäitajad
Avatud
$18.900
Kõrge
$19.383
Madal
$18.689
Maht
0.42M
Ettevõtte fundamentaalnäitajad
Turukapitalisatsioon
356.4M
Tööstusharu
Health Information Services
Riik
United States
Kauplemisstatistika
Keskmine maht
0.37M
Börs
NCM
Valuuta
USD
52 nädala vahemik
Tehisintellekti analüüsiaruanne
Viimati uuendatud: 30. okt 2025OPRX Analysis: Navigating OptimizeRx's Volatile Growth Path
Recent Price Movements
- July-August Transition: Shares jumped 37% on August 8 (12.84→17.30) with volume 5x average
- September Rally: Steady climb from 17.16 (Sept 2) to 20.51 (Sept 29) - 19.5% gain
- Current Position: Trading at $20.56 (Oct 29) after hitting $22.25 weekly high
- Pattern Alert: 3 failed attempts to hold above $22 since late September
Key Catalysts
- October 10 Analyst Boost: JMP Securities raised target to $23 (+15% from current)
- AI Prediction Signals:
- Short-term projections: +1.1% (D1), +1.7% (D2), +2.5% (D3)
- High-confidence bullish signal (81.1% AI confidence)
- Volume Surges: 3 recent spikes (584k on Aug 28, 662k on Sept 29, 421k on Oct 24)
Strategic Considerations
Strengths
- Explosive revenue growth (55.2% YoY)
- Strong institutional interest (4.9x average volume days)
- Healthcare tech positioning in growing sector
Concerns
- Profitability challenges (Negative ROE: -8.2%)
- Heavy debt load (24.29 Debt/Equity ratio)
- Technical resistance at $22 level
Actionable Insights
- Entry Window: Current price ($20.56) near support level ($20.55)
- Trade Parameters:
- Stop Loss: $18.48 (10% downside protection)
- Take Profit: $22.50 (9.4% upside)
- Alternative Entries: $20.64-$21.08 range
- Holding Strategy: 1-2 week horizon aligns with AI predictions
Final Perspective
OptimizeRx presents a high-growth opportunity tempered by financial health concerns. The combination of analyst upgrades, AI bullishness, and technical support near current levels creates a favorable risk/reward scenario for short-term traders. Long-term investors should monitor debt management and profitability improvements.
Disclaimer: This analysis references historical data and AI predictions that may not reflect future performance. Consult a financial advisor before making investment decisions. Past performance does not guarantee future results.
Seotud uudised
JMP Securities Maintains Market Outperform on OptimizeRx, Raises Price Target to $23
JMP Securities analyst Constantine Davides maintains OptimizeRx with a Market Outperform and raises the price target from $20 to $23.
Tehisintellekti ennustusBeta
Tehisintellekti soovitus
Uuendatud kell: 4. nov 2025, 17:09
65.0% Kindlus
Risk ja kauplemine
Sisenemispunkt
$19.62
Võta kasum
$20.97
Peata kahjum
$17.52
Põhitegurid
Seotud aktsiad
Püsi kursis
Määrake hinnateavitused, hankige tehisintellekti analüüsi uuendusi ja reaalajas turuuudiseid.